Abstract
Objective: To study the immunomodulatory effect of teriflunomide on innate and adaptive immune cell populations through a pilot, open-label, observational study in a cohort of patients with relapsing-remitting MS.
Methods: Blood lymphocytes were isolated from 10 patients with MS before and after 3 or 12 months of treatment. Adaptive and innate immune cell subsets were analyzed by flow cytometry as follows: B cells (memory, regulatory, and mature subsets), T cells (effector and regulatory subsets), and natural killer (NK) cells (CD56dim and CD56bright subsets).
Results: Our results show that teriflunomide significantly reduces absolute counts of total CD19+ B cells and mature and regulatory B-cell subsets. T cells were affected to a lesser extent, with a trend in reduction of absolute counts for both T effector CD4+ cells (Th1, Th17 and Th1/17) and T regulatory CD8+ and CD4+ cells. Teriflunomide had no detectable effect on NK-cell numbers.
Conclusions: In our small cohort, teriflunomide treatment affects mainly and significantly on B-cell numbers, while having a milder effect on T-cell numbers. Larger cohorts are necessary to confirm these findings and understand the effect of teriflunomide on the functionality of these cells.
GLOSSARY
- EDSS=
- Expanded Disability Status Scale;
- IFNγ=
- interferon gamma;
- NK=
- natural killer;
- RR-MS=
- relapsing-remitting MS;
- Teff=
- effector T cell;
- Treg=
- regulatory T cell
The main mechanism of action of teriflunomide, a drug approved for treatment of relapsing-remitting MS (RR-MS), relies on the inhibition of dihydroorotate dehydrogenase, which catalyzes de novo biosynthesis of pyrimidines. Cells with high proliferative rates, such as activated lymphocytes, are therefore affected by teriflunomide.1 Accordingly, treatment with teriflunomide decreases proliferation of T and B lymphocytes.2 Clinical trials (teriflunomide multiple sclerosis oral and teriflunomide oral in people with relapsing multiple sclerosis)3 have shown that teriflunomide treatment is associated with an early 15% mean decrease in leukocyte counts. However, the effect of teriflunomide on different immune cell subpopulations has not been properly addressed so far. Therefore, we have investigated how teriflunomide treatment affects immune cell populations in MS.
METHODS
Flow cytometry analysis.
Mononuclear cells were isolated from the peripheral blood by Ficoll gradient centrifugation (Lympholyte-H, Cedarlane), and flow cytometry analysis, using the BD LSRFortessa flow cytometer and FACSDiva 7 Software, was performed in 4 tubes using the following conjugated antibodies (Becton Dickinson, Franklin Lakes, NJ): anti-CD3 (V500), anti-CD4 (allophycocyanin [APC]-H7), anti-CD8 (PercCP-Cy5.5), anti-CD28 (phycoerythrin [PE], anti-CD25 (PE.Cy7), anti-CD127 (BV421), anti-CD45RA (APC), anti-CCR6 (APC), anti-CD161 (B421), anti-CCR4 (PE.Cy7), and anti-CXCR3 (PE) for effector (Teff) and regulatory T (Treg) cells; anti-CD19 (PE.Cy7), anti-CD38 (APC), and anti-CD24 (PE) for B cells; and anti-CD3 (V500), anti-CD16 (PerCp-Cy5.5), and anti-CD56 (BV421) for natural killer (NK) cells.
Flow-Count Fluorospheres (Beckman Coulter, Galway, Ireland) were used to obtain absolute cell counts.
MS patient cohort.
The longitudinal, open-label, observational study was performed on a cohort of 10 patients with RR-MS; of these, 3 were analyzed before treatment (T0) and after 3 months (T3), and 7 at T0 and after 12 months (T12) of treatment. The 3 patients followed for 3 months (2 men and 1 woman) had a mean age of 43.6 ± 1.5 years, a mean Expanded Disability Status Scale (EDSS) score of 3.0 ± 1.5 throughout treatment, and a mean disease duration of 15.3 ± 10.5 years. One patient had been treated with mitoxantrone for 6 years previously. The 7 patients followed for 12 months were all women with a mean age of 54.8 ± 8.9 years; the mean EDSS score was 3.0 ± 1.5 and 3.1 ± 1.7 before and after 12 months of treatment, respectively, and a mean disease duration of 13.4 ± 4.8 years. One patient had been treated with cyclophosphamide and mitoxantrone 7 years previously. Other previous treatments included interferonβ-1a, interferonβ-1b, natalizumab, and dimethyl fumarate. Patients did not experience relapses during treatment.
Patients were enrolled according to the following criteria: age 18 years and older, with a diagnosis of RR-MS (Poser or McDonald criteria) and an EDSS score of 0–6.5, and able to provide written informed consent.
Ethics approval.
This study was approved by the Ethics Committee of Ospedale Policlinico San Martino—IRCCS, Genoa, Italy, No. 190/12.
Statistical analyses.
Statistical analyses were performed using Graph-Pad Prism v.6.00 (GraphPad Software, San Diego, CA). Statistical significance was evaluated using the paired Student t test (Wilcoxon matched-pairs signed-rank test). p Values ≤0.05 were considered statistically significant.
RESULTS
A preliminary assessment by flow cytometry of the effect of teriflunomide on broad immune cell subsets (CD3+T cells, CD19+B cells, and CD56+NK cells) in 3 patients after a three-month treatment indicated that CD19+B-cell percentage and numbers decreased in all 3 patients (figure 1A), while no apparent effect was observed in the other cell populations (data not shown). To further define the effect of teriflunomide, we evaluated its effect on cell number and proportion of relevant immune cell subsets after a 12-month treatment in 7 different patients. As expected, the overall lymphocyte counts in all treated patients were slightly decreased (by around 10%; data not shown).
B cells are assessed as CD3−CD14−CD19+ of which subpopulations are identified as B memory (B mem CD24+CD38−), B mature (B mat CD24+CD38low), and B regulatory (B reg CD24+CD38high). (A) A clear trend in reduction of B-cell number and percentage was observed in 3 patients treated for 3 months. (B) B-cell percentage (upper panel) and numbers (lower panel) were reduced after 1 year of treatment with teriflunomide. Data are presented as mean ± SEM for 7 treated patients with MS. *p < 0.05. (C) While the proportions of the different B-cell subpopulations did not change after 12 months of treatment (upper panel), numbers of B mat and B reg cells were decreased (*p < 0.05), and B mem cell numbers showed a clear trend to decrease (lower panel). Data are presented as mean ± SEM for 7 treated patients with MS.
B cells decrease in patients with MS during teriflunomide treatment.
A significant reduction in cell number and percentage of B cells overall was confirmed in patients treated for 12 months (figure 1B). While the proportions of the different B-cell subpopulations remained stable (figure 1C upper panel), B mature and B regulatory cell numbers were significantly decreased, and B memory cells also decreased, albeit not significantly (figure 1C lower panel).
Teriflunomide treatment slightly decreases T-cell numbers, albeit nonsignificantly.
A slight trend to reduced numbers was seen in Teff (figure 2A) and Treg (figure 2B upper panel) cells after 12 months of treatment, whereas the percentage of Teff and Treg cells did not change (figure 2C and figure 2B, lower panel).
Effector T-cell populations were assessed as Th1 (CD3+CD4+CCR6−CD161−), Th17 (CD3+CD4+CCR6+CD161+), and Th1/17 (CD3+CD4+CCR6+CD161+CXCR3highCCR4low). Regulatory T-cell subpopulations were assessed as CD3+CD4+ (including Treg CD25+CD127− and Treg-naive CD45RA+CD25low) and CD3+CD8+ (including Treg CD28− and Treg–naive CD28−CD45RA+). (A) T effector cell numbers show a trend in decrease after 12 months of treatment. (B) The proportion between different regulatory T-cell subsets is not affected by teriflunomide (lower panel). The number of cells is slightly reduced in all subpopulations after 12 months of treatment (upper panel). (C) The proportion between different T effector cell subsets is not affected by the treatment. Data are presented as mean ± SEM for 7 treated patients with MS.
Teriflunomide treatment does not decrease NK-cell numbers.
Figure 3 shows that percentage and numbers of total NK cells remained stable after 12 months of treatment (figure 3, A and C), and there was no difference in the proportion and absolute counts of CD56bright and CD56dim NK cells (Figure 3, B and D).
NK cells are assessed as CD3−CD14−CD56bright and CD3−CD14−CD56dim cells. The percentage of the overall population (A) or the CD56bright and CD56dim subsets (B) did not change on treatment, nor did the actual cell number (C and D, respectively). Data are presented as mean ± SEM for 7 treated patients with MS.
DISCUSSION
MS is an inflammatory autoimmune disease involving several types of immune cells with effector and regulatory functions including T and B lymphocytes. While autoreactive CD4+ Teff cells are believed to drive autoimmune diseases when they escape central tolerance, several mechanisms have evolved to regulate their function in the periphery and prevent autoimmunity. Different Treg-cell subsets have been characterized as being able to suppress lymphocyte effector functions either directly or by acting on antigen-presenting cells, therefore preventing the development of autoimmunity. In MS, Treg suppression has been reported to be dysfunctional. The role of Th1 interferon gamma (IFNγ)-secreting cells is well known as a major protagonist in demyelinating damage in MS4; more recently, other Teff-cell subpopulations have been discovered to have a major role in the inflammatory process of MS: Th17 and Th1/17 lymphocytes secreting IFNγ and/or interleukin-17. In particular, Th1/17 cells are increased in patients with MS compared with healthy donors during active phases of disease.5 Our data show that the numbers of circulating Teff and Treg cells are slightly, albeit not significantly, decreased by teriflunomide treatment. As teriflunomide affects predominantly cells that are highly proliferative, this suggests that, in our cohort of patients who did not suffer any relapse during the period of observation, the rate of proliferation of these cells is likely low.
B lymphocytes are emerging as key player in the pathogenesis of MS. Three B-cell subsets have been described: effector, regulatory, and memory cells characterized by different roles depending on the production of antibody and of different cytokine types. Aberrant profiles of both types of cytokine responses have been observed in B cells from patients with MS.6 Our study shows that teriflunomide significantly decreases cell numbers of effector B-cell subsets, confirming the importance of targeting B cells to obtain clinical and radiologic stabilization of disease, as shown with B-cell–specific treatments such as rituximab7 and ocrelizumab.8 The effect of teriflunomide on mature B cells may be of clinical importance in view of the observed recirculation of B cells between peripheral tissues and the CNS,9 with a possible pathogenetic effect. However, teriflunomide also decreases the Breg-cell subset, as its effect on lymphocytes is not specific toward a single cell population, but rather targets proliferating cells. It is as yet unknown what are the roles of Breg cells in MS and the clinical relevance of changes induced by treatments on this cell population. However, it should be noted that efficient specific B-cell–depleting treatments such as rituximab and ocrelizumab, would also affect the Breg-cell population. In this context, beyond its current utilization as first-line therapy in MS subjects, teriflunomide could be also considered as maintenance treatment after induction therapy.
Our data show that teriflunomide treatment influences immune cell subsets involved in the pathogenesis of MS, more specifically B cells and, to a lower extent, T cells. However, further studies with larger cohorts and targeting cell functionality are necessary to clarify the basis of its efficacy in MS.
AUTHOR CONTRIBUTIONS
Ilaria Gandoglia: acquisition of data, analysis, and interpretation. Federico Ivaldi: acquisition of data. Alice Laroni: study concept and design and critical revision of the manuscript for important intellectual content. Federica Benvenuto: acquisition of data. Claudio Solaro: critical revision of the manuscript for important intellectual content. Gianluigi Mancardi: study supervision. Nicole Kerlero de Rosbo: study concept and design, critical revision of the manuscript for important intellectual content, and study supervision. Antonio Uccelli: critical revision of the manuscript for important intellectual content, study supervision.
STUDY FUNDING
No targeted funding reported.
DISCLOSURE
I. Gandoglia has received funding for travel from Biogen, Novartis, and Genzyme and honoraria from Amirall. F. Ivaldi reports no disclosures. A. Laroni has received consulting honoraria and/or speaker fees from Novartis, Genzyme, Biogen, Sanofi, Merck Serono, and Teva and received research support from Biogen. F. Benvenuto reports no disclosures. C. Solaro has served on the advisory boards for Biogen, TEVA, Novartis, Genzyme, Merck Serono, and GW Pharma; received speaking honoraria from Biogen, Merck Serono, Almirall, Teva, Novartis, GW Pharma, and Genzyme; and received research support from the Italian Multiple Sclerosis Foundation. G. Mancardi has received honoraria and financial support for travel expenses and research from Biogen, Genzyme, Teva, Merck Serono, Bayer Schering, Sanofi-Aventis, and Novartis and received research support from the Italian Multiple Sclerosis Society. N. Kerlero de Rosbo reports no disclosures. A. Uccelli has received consulting honoraria and/or speaker fees from Genentech, Athersys, Sanofi-Aventis, Tohoku University Graduate School of Medicine, Roche, Biogen, Genzyme, Teva, Novartis, and Merck Serono; served on the scientific advisory board for Genentech, Roche, and Allergan; and received research support from Bayer Schering, Sanofi-Aventis, the Italian Ministry of Health, Regione Liguira Progetto LIMONTE, Ricera Sanitaria Regionale, and Fondazione CARIGE. Go to Neurology.org/nn for full disclosure forms.
ACKNOWLEDGMENT
The authors thank the nursing staff of the Neurological Clinic of Genoa for their help with patients, and the patients themselves for their cooperation.
Footnotes
↵* These authors contributed equally as last authors to this work.
Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was funded by the authors.
- Received April 26, 2017.
- Accepted in final form August 10, 2017.
- Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
